SCHEMBL25345985

SCHEMBL25345985

COc1cccc(-c2ccccc2B(O)O)c1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.60
ORAI1 Q96D31 1/20 0.53
ORAI2 Q96SN7 1/20 0.53
ORAI3 Q9BRQ5 1/20 0.53
MAPT P10636 5/20 0.52
ALDH1A1 P00352 3/20 0.52
KDM4E B2RXH2 3/20 0.52
TP53 P04637 2/20 0.52
LMNA P02545 1/20 0.52
CYP3A4 P08684 1/20 0.52
HPGD P15428 1/20 0.52
ALOX15 P16050 1/20 0.52
ALOX12 P18054 1/20 0.52
MAPK1 P28482 1/20 0.52
HSD17B10 Q99714 1/20 0.52
ERN1 O75460 2/20 0.47
TLR2 O60603 1/20 0.47
TLR1 Q15399 1/20 0.47
TLR6 Q9Y2C9 1/20 0.47
MEN1 O00255 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14015084 0.85 ENPP2 (0.69) ENPP2ORAI1ORAI2ORAI3ALDH1A1
SCHEMBL8004728 0.84 KDM4E (0.70) MAPTALDH1A1KDM4ETP53LMNA
SCHEMBL31536724 0.83 ALDH1A1 (0.61) MAPTALDH1A1KDM4ETP53LMNA
SCHEMBL7772568 0.83 ENPP2 (0.65) ENPP2ORAI1ORAI2ORAI3MAPT
SCHEMBL1492289 0.83 ENPP2 (0.65) ENPP2ORAI1ORAI2ORAI3MAPT
SCHEMBL30335989 0.77 ALDH1A1 (0.58) ENPP2MAPTALDH1A1KDM4ETP53
SCHEMBL7150727 0.77 ALDH1A1 (0.58) ENPP2MAPTALDH1A1KDM4ETP53
SCHEMBL23807 0.76 ENPP2 (1.00) ENPP2ORAI1ORAI2ORAI3MAPT
SCHEMBL29466484 0.76 ENPP2 (1.00) ENPP2ORAI1ORAI2ORAI3MAPT
Syringol SCHEMBL27708099 0.76 KDM4E (0.70) ENPP2ORAI1ORAI2ORAI3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4523747-A2 GLP-1R RECEPTOR AGONIST COMPOUND AND USE THEREOF Suzhou Vincentage Pharma Co., Ltd (CN) 2025-03-19 EP disclosed
EP-4212527-B1 GLP-1R RECEPTOR AGONIST COMPOUND AND USE THEREOF SUZHOU VINCENTAGE PHARMA CO LTD (CN) 2024-11-27 EP disclosed
US-11773087-B2 GLP-1R receptor agonist compound and use thereof SUZHOU VINCENTAGE PHARMA CO., LTD (CN) 2023-10-03 US disclosed
US-20230257369-A1 GLP-1R RECEPTOR AGONIST COMPOUND AND USE THEREOF Chengdu Vincentage Pharma Co., Ltd. (CN) 2023-08-17 US disclosed
EP-4212527-A1 GLP-1R RECEPTOR AGONIST COMPOUND AND USE THEREOF Suzhou Vincentage Pharma Co., Ltd (CN) 2023-07-19 EP disclosed
WO-2022116693-A1 GLP-1R RECEPTOR AGONIST COMPOUND AND USE THEREOF 苏州闻泰医药科技有限公司 2022-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257369-A1 GLP-1R RECEPTOR AGONIST COMPOUND AND USE THEREOF GLP1R, GIPR, GPR119 ENPP2 741/4885ORAI1 1392/4885ORAI2 1751/4885
US-11773087-B2 GLP-1R receptor agonist compound and use thereof GLP1R, GIPR, GPR119 ENPP2 741/4885ORAI1 1392/4885ORAI2 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.